sb623
Cell therapyexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01287936)
Timeline
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sb623
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02416492 | Phase 2 | Jan 1, 2016 | SanBio, Inc., University of California, Los Angeles |
| NCT02448641 | Phase 2 | Jan 1, 2016 | SanBio, Inc., Stanford University, Sunovion |
| NCT01287936 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | Emory University, Northwestern University, SanBio, Inc., Stanford University, University of Alabama, Birmingham, University of Pittsburgh |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SanBio, Inc. | For profit | 3 | 3 | 1 | 2011 |
| Stanford University | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Sunovion | For profit | 1 | 0 | 1 | 2016 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2011 |
8 organizations
Page 1 / 1